TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Holders of 5% or more of TCRX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of TScan Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13G/A | 15.00%7.86M shares | +4.10 ppfrom 10.90% | Feb 14, 20252 filings | Aug 14, 2025 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.99%5.58M shares | 0.00 ppfrom 9.99% | May 15, 20252 filings | May 15, 2026 | SEC |
| Adage Capital Partners GP, L.L.C. | 13G/A | 7.13%3.50M shares | – | Feb 12, 20251 filing | Feb 12, 2025 | SEC |
| K2 HealthVentures Equity Trust LLC | 13G/A | 6.90%3.60M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Readout Capital, LP | 13G | 5.40%3.45M shares | New | Sep 25, 20261 filing | Sep 25, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on TScan Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 20264:12 PM ET | Readout Capital, LPand 2 others | 13G | 5.40%3.45M shares | New | Sep 21, 2026 | SEC |
| May 15, 20264:13 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.58M shares | 0.00 ppfrom 9.99% | Mar 31, 2026 | SEC |
| Aug 14, 20257:06 AM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 15.00%7.86M shares | +4.10 ppfrom 10.90% | Jun 30, 2025 | SEC |
| Aug 12, 20259:07 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 2.52%1.35M shares | –Below 5% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 1.80%958.4K shares | −3.60 ppfrom 5.40%Below 5% | Jun 30, 2025 | SEC |
| May 15, 20254:40 PM ET | Biotechnology Value Fund L Pand 9 others | 13G/A | 9.99%5.26M shares | – | Mar 31, 2025 | SEC |
| May 15, 20252:19 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 1.30%662.8K shares | –Below 5% | Mar 31, 2025 | SEC |
| Apr 24, 20259:12 AM ET | BlackRock, Inc. | 13G/A | 5.40%2.83M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20254:33 PM ET | K2 HealthVentures Equity Trust LLCand 2 others | 13G/A | 6.90%3.60M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20259:00 AM ET | Lynx1 Capital Management LPand 1 other | 13G/A | 10.90%5.36M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:38 AM ET | Adage Capital Partners GP, L.L.C.and 3 others | 13G/A | 7.13%3.50M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell TScan Therapeutics, Inc. shares.
No Form 144 notices for TScan Therapeutics, Inc. are on file.